This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Etirinotecan pegol
DrugBank Accession Number
DB14951
Background

Etirinotecan pegol is under investigation in clinical trial NCT01663012 (Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma).

Type
Small Molecule
Groups
Investigational
Synonyms
  • Etirinotecan pegol
External IDs
  • NKTR-102

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Etirinotecan pegol.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Etirinotecan pegol.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Etirinotecan pegol.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Etirinotecan pegol.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

ATC Codes
L01XX56 — Etirinotecan pegol
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
LJ16641SFT
CAS number
848779-32-8
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
Not Available
Wikipedia
Nektar_Therapeutics

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentBreast Cancer / Metastasis1
3CompletedTreatmentLocally Recurrent Breast Cancer / Metastatic Breast Cancer1
2CompletedTreatmentAdvanced Non Small Cell Lung Cancer (NSCLC) / Extensive-stage Small Cell Lung Cancer (SCLC) / Metastatic Breast Cancer / Non-small Cell Lung Cancer (NSCLC), Recurrent / Recurrent Small Cell Lung Cancer (SCLC) / Tumors Metastatic to Brain1
2CompletedTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligodendroglioma (AO) / Glioblastoma Multiforme (GBM)1
2CompletedTreatmentBreast Cancer / Tumors1
2CompletedTreatmentColorectal Carcinoma (CRC)1
2CompletedTreatmentColorectal Carcinoma (CRC) / Tumors1
2CompletedTreatmentMetastatic Non-Small Cell Lung Cancer / Non-small Cell Lung Cancer (NSCLC), Recurrent1
2CompletedTreatmentOvarian Cancer / Tumors1
2CompletedTreatmentRecurrent Small Cell Lung Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at May 20, 2019 14:37 / Updated at February 21, 2021 18:55